These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 1566739)
1. The decline in new drug development. Rumore MM Am Pharm; 1992 Apr; NS32(4):73-8. PubMed ID: 1566739 [TBL] [Abstract][Full Text] [Related]
2. In search of sustainability: process R&D in light of current pharmaceutical industry challenges. Federsel HJ Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405 [TBL] [Abstract][Full Text] [Related]
4. The antibiotic pipeline--challenges, costs, and values. Wenzel RP N Engl J Med; 2004 Aug; 351(6):523-6. PubMed ID: 15295041 [No Abstract] [Full Text] [Related]
5. Drug life-cycle technologies. Fleming E; Ma P Nat Rev Drug Discov; 2002 Oct; 1(10):751-2. PubMed ID: 12360253 [No Abstract] [Full Text] [Related]
6. Key factors in the rising cost of new drug discovery and development. Dickson M; Gagnon JP Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789 [No Abstract] [Full Text] [Related]
7. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics. Fitzgerald GA Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453 [TBL] [Abstract][Full Text] [Related]
8. The demise of the blockbuster? Cutler DM N Engl J Med; 2007 Mar; 356(13):1292-3. PubMed ID: 17392299 [No Abstract] [Full Text] [Related]
9. Success in an uneven market. Russo E Nature; 2003 Jul; 424(6948):597. PubMed ID: 12891372 [No Abstract] [Full Text] [Related]
10. Drugs: budget busters or cost cutters in future health care? Egger E Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640 [No Abstract] [Full Text] [Related]
11. The end of the beginning? Nat Rev Drug Discov; 2006 Sep; 5(9):705. PubMed ID: 17001798 [No Abstract] [Full Text] [Related]
13. Drug delivery for optimised products: from product life-cycle management to first-generation product concepts. Bhatt PP Expert Opin Drug Deliv; 2005 Jan; 2(1):1-2. PubMed ID: 16296731 [No Abstract] [Full Text] [Related]
14. Generic drugs: are they the future for affordable medicine? The Lancet Oncology Lancet Oncol; 2018 Feb; 19(2):149. PubMed ID: 29413460 [No Abstract] [Full Text] [Related]
15. Generic medicines: solutions for a sustainable drug market? Dylst P; Vulto A; Godman B; Simoens S Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572 [TBL] [Abstract][Full Text] [Related]
16. Decline in economic returns from new drugs raises questions about sustaining innovations. Berndt ER; Nass D; Kleinrock M; Aitken M Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104 [TBL] [Abstract][Full Text] [Related]
17. Complementary new approaches enable repositioning of failed drug candidates. Tartaglia LA Expert Opin Investig Drugs; 2006 Nov; 15(11):1295-8. PubMed ID: 17040191 [TBL] [Abstract][Full Text] [Related]
18. The pharmaceutical industry--to whom is it accountable? Holmer AF N Engl J Med; 2000 Nov; 343(19):1415; discussion 1417. PubMed ID: 11183877 [No Abstract] [Full Text] [Related]
19. Embedding sustainable practices into pharmaceutical R&D: what are the challenges? Sneddon H Future Med Chem; 2014; 6(12):1373-6. PubMed ID: 25329193 [No Abstract] [Full Text] [Related]
20. Looking forward in pharmaceutical process chemistry. Davies IW; Welch CJ Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]